SISU Soy Isoflavones Extra Strength
Natural health product licensed in Canada
- Other names
- SISU Soy Isoflavones
- Licence holder
- SISU
- NPN or DIN-HM
- 80047788
- Status
- Inactive licence
- Licence date
- 24 January 2014
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Stéarate de magnésium, Cellulose microcristalline, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes ménopausées et en postménopause | Not specified | 2 Capsule | 1 day |
Uses authorised in Canada
Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium & vitamin D. May reduce severe and frequent menopausal symptoms (such as hot flashes &/or night sweats).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are taking blood thinners. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, &/or uterine fibroids. Consult a health care practitioner prior to use if you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine). Consult a health care practitioner prior to use if you are taking hormone replacement therapy (HRT), including thyroid hormone replacement therapy. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort &/or tenderness, or if you experience a recurrence of menstruation &/or uterine spotting.
Source
Official Health Canada record, licence 80047788
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.